Notice: This company has been marked as potentially delisted and may not be actively trading. Reata Pharmaceuticals (RETA) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Arbe Robotics (NASDAQ:ARBE) Stock Quotes, Forecast and News SummaryNovember 1, 2024 | benzinga.comWhat to Know: How Israel Could Retaliate Against IranOctober 27, 2024 | nytimes.comLazard hires veteran healthcare dealmaker Colocci as vice chairmanMay 9, 2024 | investing.comLevi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action SettlementJanuary 25, 2024 | markets.businessinsider.comUpward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024December 29, 2023 | msn.comBiogen cuts annual profit forecast on higher deal costs (Nov 8)November 14, 2023 | investing.comBiogen lowers full-year earnings guidance, 3Q revenue beats expectationsNovember 8, 2023 | proactiveinvestors.comBiogen cuts annual profit forecast as higher costs persistNovember 8, 2023 | investing.comBraun Stacey Associates Inc. Lowers Stake in Reata Pharmaceuticals, Inc. (NASDAQ:RETA)Braun Stacey Associates Inc. cut its stake in Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) by 47.0% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 164,775 shares of the company's stock after selling 146,235 shares during the peOctober 13, 2023 | marketbeat.comReata Pharmaceuticals, Inc. (NASDAQ:RETA) Given Consensus Recommendation of "Hold" by BrokeragesReata Pharmaceuticals, Inc. (NASDAQ:RETA - Get Free Report) has been given a consensus rating of "Hold" by the thirteen ratings firms that are covering the stock, MarketBeat.com reports. Nine research analysts have rated the stock with a hold recommendation and four have issued a buy recommendatioOctober 13, 2023 | marketbeat.comTop Growth Stocks for October 2023October 1, 2023 | msn.comBiogen Inc.: Biogen Completes Acquisition of Reata PharmaceuticalsSeptember 26, 2023 | finanznachrichten.deBiogen Completes Acquisition of Reata PharmaceuticalsSeptember 26, 2023 | finance.yahoo.comTrading was temporarily halted for "RETA" at 07:09 PM with a stated reason of "News pending."September 26, 2023 | marketbeat.comReata Pharmaceuticals, Inc. (NASDAQ:RETA) Is Expected To Breakeven In The Near FutureSeptember 13, 2023 | finance.yahoo.comFirst Light Asset Management LLC Sells 475,525 Shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA)First Light Asset Management LLC decreased its holdings in shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) by 23.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,586,928 shares of theSeptember 12, 2023 | marketbeat.comDoes Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy?September 9, 2023 | finance.yahoo.comHighTower Advisors LLC Decreases Position in Reata Pharmaceuticals, Inc. (NASDAQ:RETA)HighTower Advisors LLC trimmed its position in shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) by 6.5% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 48,978 shares of the company's stock after sSeptember 7, 2023 | marketbeat.comCredit Suisse AG Purchases 2,334 Shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA)Credit Suisse AG boosted its position in Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) by 6.0% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 41,476 shares of the company's stock after purchasing an additional 2,334 shareSeptember 1, 2023 | marketbeat.comSwiss National Bank Reduces Stake in Reata Pharmaceuticals, Inc. (NASDAQ:RETA)Swiss National Bank reduced its stake in Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) by 10.2% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 58,200 shares of the company's stock afteAugust 31, 2023 | marketbeat.com3,204 Shares in Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Purchased by Pictet Asset Management SAPictet Asset Management SA bought a new stake in Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 3,204 shares of the company's stock, valued at approximately $291,000. SeveralAugust 30, 2023 | marketbeat.comREATA PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale ...August 28, 2023 | businesswire.comReata Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:RETA)Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Get Free Report) was the recipient of some unusual options trading activity on Friday. Investors acquired 5,018 put options on the company. This is an increase of 180% compared to the typical volume of 1,794 put options.August 25, 2023 | marketbeat.comReata Pharmaceuticals, Inc. (NASDAQ:RETA) Receives Consensus Recommendation of "Hold" from AnalystsReata Pharmaceuticals, Inc. (NASDAQ:RETA - Get Free Report) has been given an average recommendation of "Hold" by the thirteen research firms that are currently covering the stock, Marketbeat Ratings reports. Nine investment analysts have rated the stock with a hold recommendation and four have assAugust 24, 2023 | marketbeat.comUS Bancorp DE Purchases 8,947 Shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA)US Bancorp DE lifted its position in Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) by 1,280.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 9,646 shares of the company's stock after purchasing an additional 8,947 shares dAugust 23, 2023 | marketbeat.comStockNews.com Initiates Coverage on Reata Pharmaceuticals (NASDAQ:RETA)StockNews.com began coverage on shares of Reata Pharmaceuticals in a research note on Wednesday. They issued a "sell" rating for the company.August 23, 2023 | marketbeat.comReata Pharmaceuticals, Inc. (NASDAQ:RETA) Shares Acquired by Zurcher Kantonalbank Zurich CantonalbankZurcher Kantonalbank Zurich Cantonalbank grew its stake in Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) by 23.1% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 6,497 shares of the company's stock afterAugust 20, 2023 | marketbeat.comCantor Fitzgerald Reiterates Reata Pharmaceuticals Inc - (RETA) Neutral RecommendationAugust 15, 2023 | msn.comCantor Fitzgerald Reiterates "Neutral" Rating for Reata Pharmaceuticals (NASDAQ:RETA)Cantor Fitzgerald reissued a "neutral" rating and set a $172.00 price objective on shares of Reata Pharmaceuticals in a report on Tuesday.August 15, 2023 | marketbeat.comBiondo Investment Advisors LLC Takes $323,000 Position in Reata Pharmaceuticals, Inc. (NASDAQ:RETA)Biondo Investment Advisors LLC purchased a new stake in Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The firm purchased 3,550 shares of the company's stock, valued at approximately $323,000. A number of otherAugust 11, 2023 | marketbeat.comReata Pharmaceuticals Unusual Options Activity For August 11August 11, 2023 | benzinga.comReata Pharmaceuticals (RETA) Gets a Hold from BarclaysAugust 9, 2023 | markets.businessinsider.comReata Pharmaceuticals (NASDAQ:RETA) Earns Sell Rating from Analysts at StockNews.comStockNews.com initiated coverage on Reata Pharmaceuticals in a research report on Monday. They set a "sell" rating for the company.August 8, 2023 | marketbeat.comEquities Analysts Issue Forecasts for Reata Pharmaceuticals, Inc.'s Q2 2025 Earnings (NASDAQ:RETA)Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) - Research analysts at Zacks Research boosted their Q2 2025 EPS estimates for shares of Reata Pharmaceuticals in a research note issued on Wednesday, August 2nd. Zacks Research analyst S. Ganoria now anticipates that the company will post eaAugust 4, 2023 | marketbeat.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RETA, EQRX, RVMDAugust 2, 2023 | markets.businessinsider.comReata Pharmaceuticals Inc - (RETA) Price Target Increased by 53.21% to 175.90August 2, 2023 | msn.comIntegrated Wealth Concepts LLC Purchases Shares of 11,294 Reata Pharmaceuticals, Inc. (NASDAQ:RETA)Integrated Wealth Concepts LLC bought a new position in Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 11,294 shares of the company's stock, valued at approximaAugust 1, 2023 | marketbeat.comCitigroup Downgrades Reata Pharmaceuticals (NASDAQ:RETA) to NeutralCitigroup downgraded Reata Pharmaceuticals from a "buy" rating to a "neutral" rating in a research note on Tuesday.August 1, 2023 | marketbeat.comBiogen's Bold $7.3B Acquisition Of Reata: Analyzing The Impact On InvestorsJuly 29, 2023 | msn.comReata Pharmaceuticals (NASDAQ:RETA) Stock Rating Lowered by SVB SecuritiesSVB Securities cut Reata Pharmaceuticals from an "outperform" rating to a "market perform" rating in a report on Friday.July 28, 2023 | marketbeat.comBiogen agrees to acquire neurological disease specialist Reata Pharmaceuticals at 60% premiumJuly 28, 2023 | investing.comRETA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Reata Pharmaceuticals, Inc. Is Fair to ShareholdersJuly 28, 2023 | technews.tmcnet.comBiogen to Acquire Reata PharmaceuticalsJuly 28, 2023 | finance.yahoo.comReata Pharmaceuticals Shares Soar on Takeover by Biogen >RETAJuly 28, 2023 | marketwatch.comWhy Is Reata Pharmaceuticals (RETA) Stock Up 53% Today?July 28, 2023 | markets.businessinsider.comTrading was temporarily halted for "RETA" at 06:07 AM with a stated reason of "News pending."July 28, 2023 | marketbeat.comExpert Ratings for Reata PharmaceuticalsJuly 24, 2023 | markets.businessinsider.com5,396 Shares in Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Bought by Raymond James Financial Services Advisors Inc.Raymond James Financial Services Advisors Inc. bought a new stake in Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,July 20, 2023 | marketbeat.comReata Pharmaceuticals, Inc. (NASDAQ:RETA) Shares Sold by DekaBank Deutsche GirozentraleDekaBank Deutsche Girozentrale reduced its stake in shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) by 24.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,000 shareJuly 16, 2023 | marketbeat.comMoody Aldrich Partners LLC Invests $4.50 Million in Reata Pharmaceuticals, Inc. (NASDAQ:RETA)Moody Aldrich Partners LLC bought a new position in shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 49,529 shares of the company's stock, valued at approximately $July 14, 2023 | marketbeat.com Get Reata Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RETA and its competitors with MarketBeat's FREE daily newsletter. Email Address Vladimir Lenin was right… (Ad)The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier. Including the name of the #1 company to buy. RETA Media Mentions By Week RETA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RETA News Sentiment▼0.000.59▲Average Medical News Sentiment RETA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RETA Articles This Week▼00▲RETA Articles Average Week Get Reata Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RETA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TEVA News Today BGNE News Today UTHR News Today VTRS News Today RPRX News Today SMMT News Today GMAB News Today INSM News Today BMRN News Today RDY News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RETA) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reata Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Reata Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
